Mammography screening participation

Six microsimulation models evaluated screening strategies for a hypothetical cohort of 1,000 average-risk 40-year-old female persons. Five efficient digital breast tomosynthesis screening strategies yielded median breast cancer mortality reductions of 25.4% to 41.7%, life-years gained of 120.8 to 229.7, and 6.7 to 11.5 deaths averted per 1,000 women. Biennial screening from ages 40-79 or 45-79 resulted in greater incremental gains in mortality reduction per mammogram compared to annual screening or strategies with start age 50 and cessation age 74. For Black female persons, three efficient strategies yielded mortality reductions of 31.2% to 39.6%, life-years gained of 219.4 to 309.0, and 11.7 to 15.5 deaths averted per 1,000 women. False-positive recalls ranged from 873 to 2,224 and overdiagnosed cases from 12 to 25 per 1,000 women across strategies.

View Source →

Six microsimulation models evaluated screening strategies in a hypothetical cohort of 1,000 average-risk 40-year-old female persons. Five efficient biennial DBT screening strategies yielded median breast cancer mortality reductions of 25.4% to 41.7%, 120.8 to 229.7 life-years gained, and 6.7 to 11.5 deaths averted compared to no screening. Harms included 873 to 2,224 false-positive recalls and 12 to 25 overdiagnosed cases per 1,000 women over a lifetime. Strategies with biennial screening, start ages at 40 or 45, and cessation age at 79 resulted in greater incremental gains in mortality reduction per mammogram compared with strategies involving annual screening, start age at 50, or cessation age at 74.

View Source →

A meta-analysis of 11 cohort studies from Asia, Europe, and North America found that screening mammography reduced breast cancer mortality by 35% (adjusted HR = 0.65; 95% CI = 0.54 to 0.79; p = 0.0001). The systematic review screened 1,326 articles, ultimately including 11 cohort studies of women aged 40 years and older. Study heterogeneity was high (I² = 91%), and a random effects model was used. These findings align with prior meta-analyses showing mortality reductions of 17–49% across different age groups and populations. Funnel plot analysis indicated some publication bias with asymmetric distribution (4 plots right, 7 plots left).

View Source →

In this randomized controlled trial across six NHS Breast Screening Programme centres, 26,054 women aged 50-70 who missed their first screening appointment were analyzed. Women who received a second fixed-date timed appointment had a 22% participation rate (2,861 of 12,807) compared to 12% (1,632 of 13,247) in the control group who received a call-to-book letter. The relative risk of participation was 1.81 (95% CI 1.70-1.93; p<0.0001). The trial enrolled 33,146 non-attenders between June 2014 and September 2015, demonstrating that simply having a scheduled appointment substantially increases screening uptake.

View Source →

EUSOBI and 30 national breast radiology bodies issued a consensus position supporting population-based mammography screening. According to the International Agency for Research on Cancer, mortality reduction is 40% for women aged 50-69 years who take up the screening invitation. The probability of false-positive needle biopsy is less than 1% per screening round, and overdiagnosis accounts for only 1-10% over a 20-year screening period. Mortality reduction was also observed for women aged 40-49 years and 70-74 years, though classified as 'limited evidence.' The consensus recommends biennial screening for average-risk women aged 50-69 as first priority, extension to 73-75 years biennially as second priority, and annual screening from ages 40-45 to 49 as third priority.

View Source →

In a randomized controlled trial of 244 African-American women aged 41-65 who had not had a mammogram in the last 15 months, a mailed interactive DVD intervention was five times more effective than usual care at promoting mammography screening at 6-month follow-up among women earning less than $30,000 (OR = 5.3). African-American women experience greater breast cancer mortality than Caucasians (OR = 1.38) despite lower incidence, underscoring the importance of screening adherence. The trial randomized participants to three arms: mailed interactive DVD, computer-tailored telephone counseling, or usual care. Neither DVD nor phone counseling produced significant effects for women with household incomes above $30,000.

View Source →

In a prospective screening study of 198 women from breast cancer families without demonstrable BRCA1/2 mutations, annual mammography from age 30 onwards yielded an overall 10-year survival of 88%. The majority of detected tumours (160/194, 84%) were ER-positive and/or low grade, with 92% 10-year survival in this subgroup. The combined risk of developing breast cancer causing death within 10 years before age 50 was 1% or less when subjected to annual mammography and current treatment. Total follow-up comprised 1,513 patient-years. These women carried approximately twice the population risk of breast cancer.

View Source →

A two-group cluster randomized controlled trial across 50 Korean American religious organizations in Chicago enrolled 428 married Korean American women aged 40 or older who had not had a mammogram in the past year, along with their husbands (211 couples in intervention, 217 in control). The KIM-CHI culturally targeted couples intervention showed statistically significant increases in mammography uptake compared to the attention control group at both 6 months and 15 months postintervention. The intervention specifically addressed culture-specific health beliefs and included husbands as participants in the educational program.

View Source →

A prospective cohort study followed all Norwegian women aged 50-79 between 1986 and 2009, accumulating 15,193,034 person-years of observation. During this period, 1,175 breast cancer deaths occurred among women diagnosed after being invited to screening, compared with 8,996 deaths among uninvited women. After adjusting for age, birth cohort, county of residence, and national mortality trends, the breast cancer mortality rate ratio for invited versus uninvited women was 0.72 (95% CI 0.64 to 0.79), representing a 28% reduction. The number needed to invite to prevent one breast cancer death was estimated at 368 women (95% CI 266 to 508) over a lifetime of biennial screening from ages 50-69.

View Source →

In a case-control analysis of 28 Hodgkin's lymphoma survivors who developed 39 breast cancers, mammographic screening detected the index breast cancer in 17 of 28 patients (60.7%), compared to detection by palpable lump in 8 patients (28.6%) and clinical examination in 2 patients (7.1%). The median age at Hodgkin's lymphoma diagnosis was 25.3 years, with breast cancer developing at a median age of 45.3 years after a median interval of 16.1 years. Bilateral disease occurred in 11 women (39.2%), underscoring the heightened risk in this population.

View Source →

A cohort study of 699,628 Norwegian women aged 50-69 years followed from 1996-2010 compared breast cancer mortality between screened and nonscreened participants. The crude breast cancer mortality rate was 20.7 per 100,000 women-years in the screened cohort versus 39.7 per 100,000 women-years in the nonscreened cohort. After adjusting for calendar period, attained age, years since inclusion, and self-selection bias, women who attended the screening program had a 43% reduction in breast cancer mortality (mortality rate ratio 0.57; 95% CI 0.51-0.64). Over 15 years of follow-up, the unadjusted mortality rate ratio was 0.52 (95% CI 0.47-0.59).

View Source →

Meta-analysis and systematic review of randomized controlled trials found that screening mammography in women aged 40 to 49 may reduce mortality from breast cancer, though reductions are small — fewer than 1 death prevented per 10,000 women screened per year. The recommendation received a strength of B rating, reflecting inconsistent findings across the included RCTs. In contrast, screening women aged 50 to 69 has strong expert agreement and consistent evidence supporting mortality reduction. The guideline acknowledges that while the absolute benefit for the 40-49 age group is modest, it remains a measurable positive effect across pooled trial data.

View Source →

In this randomized controlled trial of 44,288 women aged 45-64, 22,944 were offered screening over 7 years. After 10 years of follow-up, breast cancer mortality was 14-21% lower in the screened group depending on endpoint definition (relative risk 0.82, 95% CI 0.61-1.11). Rates of locally advanced and metastatic cancer were substantially lower in the study group. For women aged 45-49 at entry (10,383 women with 6-8 years follow-up), breast cancer mortality reduction was 22% (relative risk 0.78, 95% CI 0.46-1.31). Interval cancer rates increased from 12% of control incidence in year one to 67% by year three after last screen.

View Source →